Products - Structural heart defects | Topic | NICE

Showing 4 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter
Status: PublishedRemove ‘Status: Published’ filter

Acoramidis for treating transthyretin amyloidosis with cardiomyopathy (TA1121)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 January 2026
Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy (TA1115)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 December 2025
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA984)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 June 2024
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (TA913)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 September 2023